Methadone use in relation to hepatitis C virus testing in British Columbia

Canadian Journal of Public Health

Volumn 101, Issue 6, 2010, Pages 491-494

  Buxton, Jane A ^a   Kuo, Margot E ^a   Ramji, Sabrina ^b   Yu, Amanda ^a   Krajden, Mel ^a  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Harm reduction; Hepatitis C; Injection drug use, methadone, addiction

Indexed keywords

EID: 78651291184     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03403970     Document Type: Article

References (28)

1. Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008;103(6):905-18.
2. British Columbia Centre for Excellence in HIV/AIDS. The CHASE Project: Community Report #1, 2004. Available at: http://chase.hivnet.ubc.ca/project/ pubdocs/chasedoc.htm (Accessed November 1, 2009).
3. British Columbia Centre for Excellence in HIV/AIDS. Community Health and Safety Evaluation (CHASE) Project: Final Report, 2006. Available at: http://chase.hivnet.ubc.ca/project/pubdocs/chasedoc.htm (Accessed November 7, 2009).
4. Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: Survival analysis of time to seroconversion. Epidemiol 2004;15(5):543-49.
5. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place. Am J Epidemiol 2008;168(10):1099- 109.
6. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969;280(25):1372-93.
7. Sheerin I, Green T, Sellman D, Adamson S, Deering D. Reduction in crime by drug users on a methadone maintenance therapy program in New Zealand. N Z Med J 2004;117:1190-94.
8. Chaisson RE, Moss AR, Onishi R, Osmond D, Carlson JR. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health 1987;77:169-72.
9. Lee KCK, Lim WWL, Lee SS. High prevalence of HCV in a cohort of injectors on methadone substitution treatment. J Clin Virol 2008;41(4):297-300.
10. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med 2000;67(5 & 6):423-28.
11. Novick DM. The impact of hepatitis C virus infection on methadone maintenance treatment. Mt Sinai J Med 2000;67(5 & 6):437-43.
12. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007;102(9):1454-62.
13. College of Pharmacists of British Columbia. PharmaCare/PharmaNet Policies and Procedures Manual, 2003. Available at: http://www.bcpharmacists.org/ pharmanet/resources/general.php (Accessed January, 2010).
14. Population Data BC. Data Access, 2009. Available at: http://www.popdata. bc.ca/dataaccess (Accessed January 10, 2010).
15. College of Pharmacists of British Columbia. PharmaNet Data Disclosure, 2007. Available at: http://www.bcpharmacists.org/library/G-PharmaNet/G-4- PharmaNet-Data-Disclosure/5055-PNet-Data-Disclosure-Requests.pdf (Accessed January 10, 2010).
16. Anderson JF, Warren LD. Client retention in the British Columbia Methadone Program, 1996-1999. Can J Public Health 2004;95(2):104-9.
17. Joseph H, Stancliff S, Langrod J. Methadone Maintenance Treatment (MMT): A review of historical and clinical issues. Mt Sinai J Med 2000;67(5 & 6):347-64.
18. Nosyk B, MacNab YC, Sun H, Fischer B, Marsh DC, Schechter MT, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol 2009;170(6):783-92.
19. Lehmann F, Lauzon P, Amsel R. Methadone maintenance: Predictors of outcome in a Canadian milieu. J Substance Abuse Treatment 1993;10(1):85-89.
20. Taylor-Seehafer MA. Positive youth development: Reducing the health risks of homeless youth. Am J Maternal Child Nursing 2004;29(1):36-40.
21. Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clin Infect Dis 2002;35(7):783-88.
22. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002;97(10):1289-94.
23. McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction 2001;96(7):1007-14.
24. Wood E, Spittal P, Li K, Kerr T, Miller CL, Hogg RS, et al. Inability to access addiction treatment and risk of HIV infection among injection drug users. JAIDS 2004;36(2):750-54.
25. Buxton J, Yu A, Alvarez M, Kuo M, Krajden M, Gilbert M, et al. HCV co-infection in HIV positive population in British Columbia. BMC Public Health 2010;10:225.
26. Jayaraman G, Lee B, Singh A, Preiksaitis J. Trends in testing behaviours for hepatitis C virus infection and associated determinants: Results from population-based laboratory surveillance in Alberta, Canada (1998-2001). J Viral Hep 2007;14:249-54.
27. Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, et al. The future face of coinfection - Prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. JAIDS 2004;36(2):743-49.
28. Spittal PM, Craib KJP, Teegee M, Baylis C, Christian WM, Moniruzzaman AKM, et al. The Cedar Project: Prevalence and correlates of HIV infection among young Aboriginal people who use drugs in two Canadian cities. Int J Circumpolar Health 2007;66(3):226-40.